Stock Information
Share Data
Stock Performance
Analyst Coverage
Advisor & Investor Contacts

Reports & Presentations

Interim & Annual Reports
Corporate Governance
Company Information
Board of Directors
General Meetings


SEC Filings

Advancing Medicines for a Brighter Future

Developing a pipeline of products aimed at diseases with unmet medical need

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biotechnology company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company’s lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection. Without effective treatment virtually all FAP patients progress to develop colorectal cancer. The company is also working on treatments for type 1 diabetes and primary and metastatic cancers of the brain.

eRapa™ is a proprietary oral tablet formulation of rapamycin (sirolimus). Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR is known to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis. Rapamycin is approved in the US for organ rejection in renal transplantation. It is very poorly water soluble and current formulations exhibit significant variability in systemic plasma levels. Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to improve bioavailability and achieve more consistent pharmacokinetics than existing products.

Tolimidone is an orally delivered, potent and selective inhibitor of lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. 

woman on beach

eRapa™ is a proprietary oral tablet formulation of rapamycin (sirolimus).

Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor.

biodexa researcher at work
MTX110 is currently in phase 1 of clinical trials in a study known as the MAGIC-G1.


Biodexa Pharmaceuticals PLC is listed on NASDAQ: BDRX. Visit our investor resources for shareholder information and latest news and reports.

scientist with laptop